AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20089065 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 137) answered the questionnaire
Number of subjects: 336
Study 18926277 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential newborn care intervention (birth preparedness, clean delivery and cord care, thermal care, breastfeeding promotion, danger sign recognition)
Number of subjects: 104123
Study 18926277 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential newborn care plus ThermoSpot (liquid crystal hypothermia indicator)
Number of subjects: 104123
Study 18926277 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual services of governmental and non-governmental organisations)
Number of subjects: 104123
Study 11465644 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance test (OGTT)
Number of subjects: 49
Study 11465644 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal-weight women)
Number of subjects: 49
Study 11465644 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-Ob group
Number of subjects: 49
Study 11465644 — intervention group
Group type: EXPERIMENTAL
Intervention: HT-Ob group
Number of subjects: 49
Study 9720332 — intervention group
Group type: EXPERIMENTAL
Intervention: 60% lidocaine tape applied for 2.5 hours before venipuncture
Number of subjects: 71
Study 9720332 — intervention group
Group type: COMPARATOR
Intervention: Control group (no lidocaine tape)
Number of subjects: 71
Study 9720332 — intervention group
Group type: EXPERIMENTAL
Intervention: 60% lidocaine tape
Number of subjects: 71
Study 7840753 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (200 mg)
Number of subjects: 9
Study 7840753 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 3277435 — intervention group
Group type: EXPERIMENTAL
Intervention: mezlocillin
Number of subjects: 96
Study 3277435 — intervention group
Group type: COMPARATOR
Intervention: clindamycin/gentamicin
Number of subjects: 96
Study 30736873 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnea severity measures (AHI, ODI3%, T90)
Number of subjects: 362
Study 30736873 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen desaturation index (ODI3%)
Number of subjects: 362
Study 30736873 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep time with SpO2 < 90% (T90)
Number of subjects: 362
Study 29059694 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual Medicine (MM)
Number of subjects: 52
Study 29059694 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 26045510 — intervention group
Group type: EXPERIMENTAL
Intervention: Audience Response System (ARS) embedded in lecture
Number of subjects: 92
Study 26045510 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ARS questions)
Number of subjects: 92
Study 23566745 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-α
Number of subjects: 23
Study 23566745 — intervention group
Group type: COMPARATOR
Intervention: Ringer's lactate (Control)
Number of subjects: 23
Study 21849414 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular exercise (CE; brisk walk on a treadmill)
Number of subjects: 76
Study 21849414 — intervention group
Group type: EXPERIMENTAL
Intervention: Hatha yoga (HY)
Number of subjects: 76
Study 21849414 — intervention group
Group type: COMPARATOR
Intervention: Nonactivity control condition
Number of subjects: 76
Study 19361589 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg)
Number of subjects: 0
Study 19361589 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (80 mg)
Number of subjects: 0
Study 16626943 — intervention group
Group type: EXPERIMENTAL
Intervention: New time budget measure of activity in psychosis
Number of subjects: 276
Study 15387960 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 102
Study 15387960 — intervention group
Group type: EXPERIMENTAL
Intervention: Probucol
Number of subjects: 102
Study 15387960 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 102
Study 15387960 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 11461714 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment procedure with accounted measurement error in log-transformed total rapid eye movement (REM) activity counts
Number of subjects: 0
Study 11461714 — intervention group
Group type: EXPERIMENTAL
Intervention: Likelihood-based approach accounting for measurement error
Number of subjects: 0
Study 9159697 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline pharmacotherapy
Number of subjects: 75
Study 9159697 — intervention group
Group type: COMPARATOR
Intervention: Baseline symptoms resembling tricyclic side effects
Number of subjects: 75
Study 9159697 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe depressive episodes and history of anxiety or panic disorder
Number of subjects: 75
Study 9159697 — intervention group
Group type: EXPERIMENTAL
Intervention: Dropout before completing acute phase of pharmacotherapy
Number of subjects: 75
Study 7959619 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile growth hormone (GH) secretion analysis using a computerized mathematical algorithm of pulsatility (Cluster) in children with short stature.
Number of subjects: 176
Study 7959619 — intervention group
Group type: EXPERIMENTAL
Intervention: GH secretory response to pharmacological stimuli including clonidine, growth hormone-releasing hormone (GHRH), and hypoglycemia after insulin administration in children with short stature.
Number of subjects: 176
Study 7959619 — intervention group
Group type: COMPARATOR
Intervention: Control group of prepubertal children with normal height and growth velocity.
Number of subjects: 176
Study 31669916 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot reflexology for five consecutive days
Number of subjects: 72
Study 31669916 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 72
Study 28251260 — intervention group
Group type: COMPARATOR
Intervention: PRP injection
Number of subjects: 44
Study 28251260 — intervention group
Group type: EXPERIMENTAL
Intervention: SVF injection
Number of subjects: 44
Study 26644225 — intervention group
Group type: COMPARATOR
Intervention: Fixed Dose Combination (FDC) of ceftriaxone and sulbactam
Number of subjects: 24
Study 26644225 — intervention group
Group type: EXPERIMENTAL
Intervention: FDC (3 g/24 h)
Number of subjects: 24
Study 26644225 — intervention group
Group type: EXPERIMENTAL
Intervention: FDC (3 g/12 h)
Number of subjects: 24
Study 26644225 — intervention group
Group type: EXPERIMENTAL
Intervention: Population-PK model
Number of subjects: 24
Study 24054792 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic repair
Number of subjects: 140
Study 24054792 — intervention group
Group type: COMPARATOR
Intervention: Open ventral hernia repair
Number of subjects: 140
Study 22972905 — intervention group
Group type: EXPERIMENTAL
Intervention: Spending time on others
Number of subjects: 0
Study 22972905 — intervention group
Group type: COMPARATOR
Intervention: Wasting time
Number of subjects: 0
Study 22972905 — intervention group
Group type: COMPARATOR
Intervention: Spending time on oneself
Number of subjects: 0
Study 22972905 — intervention group
Group type: COMPARATOR
Intervention: Gaining a windfall of 'free' time
Number of subjects: 0
Study 20643719 — intervention group
Group type: EXPERIMENTAL
Intervention: EHR-based decision support (clinician reminders and ADHD note template)
Number of subjects: 412
Study 20643719 — intervention group
Group type: EXPERIMENTAL
Intervention: EHR-based decision support (ADHD note template)
Number of subjects: 412
Study 17947627 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Decision Support System (CDSS)
Number of subjects: 164
Study 17947627 — intervention group
Group type: COMPARATOR
Intervention: Control (ED physician assessment)
Number of subjects: 164
Study 16648740 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity back school
Number of subjects: 299
Study 16648740 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 299
Study 16648740 — intervention group
Group type: COMPARATOR
Intervention: High-intensity back school
Number of subjects: 299
Study 12671332 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin‐converting enzyme inhibitor ramipril
Number of subjects: 0
Study 12671332 — intervention group
Group type: COMPARATOR
Intervention: Beta blocker metoprolol
Number of subjects: 0
Study 12671332 — intervention group
Group type: COMPARATOR
Intervention: Dihydropyridine calcium channel blocker amlodipine
Number of subjects: 0
Study 12671332 — intervention group
Group type: COMPARATOR
Intervention: Blood pressure reduction to levels below 92 mm Hg
Number of subjects: 0
Study 12671332 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary clinical composite end point
Number of subjects: 0
Study 10870737 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 8857906 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracoscopy
Number of subjects: 21
Study 8857906 — intervention group
Group type: COMPARATOR
Intervention: Thoracotomy
Number of subjects: 21
Study 1623444 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal baclofen injections
Number of subjects: 6
Study 1623444 — intervention group
Group type: COMPARATOR
Intervention: Placebo saline injections
Number of subjects: 6
Study 6503708 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0
Study 6503708 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol
Number of subjects: 0
Study 6503708 — intervention group
Group type: EXPERIMENTAL
Intervention: Propylthiouracil (PTU)
Number of subjects: 0
Study 6503708 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31541364 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathic Manual Therapy (OMT)
Number of subjects: 19
Study 31541364 — intervention group
Group type: COMPARATOR
Intervention: Sham therapy
Number of subjects: 19
Study 30360498 — intervention group
Group type: EXPERIMENTAL
Intervention: Peanut group (n = 17)
Number of subjects: 32
Study 30360498 — intervention group
Group type: EXPERIMENTAL
Intervention: Almond group (n = 15)
Number of subjects: 32
Study 30360498 — intervention group
Group type: COMPARATOR
Intervention: Control (not applicable)
Number of subjects: 32
Study 26892312 — intervention group
Group type: EXPERIMENTAL
Intervention: K305 (3% tetracaine hydrochloride and 0.05% oxymetazoline hydrochloride)
Number of subjects: 110
Study 26892312 — intervention group
Group type: COMPARATOR
Intervention: Tetracaine hydrochloride spray
Number of subjects: 110
Study 26892312 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 110
Study 24985691 — intervention group
Group type: EXPERIMENTAL
Intervention: Unstable shoes (model MBT Fora)
Number of subjects: 40
Study 24985691 — intervention group
Group type: COMPARATOR
Intervention: Conventional sports shoes (model Adidas Bigroar)
Number of subjects: 40
Study 22412842 — intervention group
Group type: EXPERIMENTAL
Intervention: Histologic chorioamnionitis (Grade 1 or Grade 2)
Number of subjects: 195
Study 22412842 — intervention group
Group type: EXPERIMENTAL
Intervention: Infection
Number of subjects: 195
Study 22412842 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapartum fever >38°C
Number of subjects: 195
Study 22412842 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural for pain relief
Number of subjects: 195
Study 22412842 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum interleukin-8 levels
Number of subjects: 195
Study 22412842 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum interleukin-6 levels
Number of subjects: 195
Study 22412842 — intervention group
Group type: EXPERIMENTAL
Intervention: Admission WBC counts
Number of subjects: 195
Study 19281600 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone
Number of subjects: 33
Study 19281600 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 17229406 — intervention group
Group type: EXPERIMENTAL
Intervention: High frequency rTMS over the right DLPFC
Number of subjects: 20
Study 17229406 — intervention group
Group type: COMPARATOR
Intervention: SHAM (placebo)
Number of subjects: 20
Study 15185806 — intervention group
Group type: EXPERIMENTAL
Intervention: Compomer F2000
Number of subjects: 75
Study 15185806 — intervention group
Group type: COMPARATOR
Intervention: Amalgam Dispersalloy
Number of subjects: 75
Study 15185806 — intervention group
Group type: COMPARATOR
Intervention: Both Compomer and Amalgam
Number of subjects: 75
Study 12467746 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice weekly oral prednisone (5mg/kg/dose)
Number of subjects: 20
Study 12467746 — intervention group
Group type: COMPARATOR
Intervention: Untreated boys
Number of subjects: 20
Study 9853999 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased caudal slope of the tibia (group 1)
Number of subjects: 88
Study 9853999 — intervention group
Group type: COMPARATOR
Intervention: Patellofemoral pain syndrome (group 2)
Number of subjects: 88
Study 8132136 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide 100 micrograms t.i.d. s.c. starting at least 1 h before surgery and continued till the 7th postsurgical day
Number of subjects: 303
Study 8132136 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 303
Study 2485348 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral diet rich in fiber (polysaccharides of soya providing 25 gr of dietary fiber per 2,000 kilocalories)
Number of subjects: 40
Study 2485348 — intervention group
Group type: COMPARATOR
Intervention: Enteral diet poor in fiber (commonly used due to good clinical tolerance)
Number of subjects: 40
Study 779473 — intervention group
Group type: EXPERIMENTAL
Intervention: Parasympatholytic drug therapy (propantheline bromide or dycyclomine HC1)
Number of subjects: 210
Study 779473 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 210
Study 779473 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard surgery
Number of subjects: 210
Study 779473 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical and surgical therapy
Number of subjects: 210
Study 30463434 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone otoscope
Number of subjects: 1500
Study 30463434 — intervention group
Group type: COMPARATOR
Intervention: Conventional otoscope
Number of subjects: 1500
Study 27670440 — intervention group
Group type: EXPERIMENTAL
Intervention: CoQ10 100 mg daily
Number of subjects: 80
Study 27670440 — intervention group
Group type: COMPARATOR
Intervention: Control (current preventive drugs only)
Number of subjects: 80
Study 25417605 — intervention group
Group type: EXPERIMENTAL
Intervention: Microvascular dissection training on a chicken wing model
Number of subjects: 0
Study 25417605 — intervention group
Group type: COMPARATOR
Intervention: Control group performing endoscopic transantral internal maxillary artery dissection on a silicone-injected anatomical specimen
Number of subjects: 0
Study 23835722 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 % O(2)
Number of subjects: 258
Study 23835722 — intervention group
Group type: COMPARATOR
Intervention: 20 % O(2)
Number of subjects: 258
Study 22169414 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise group (n = 25)
Number of subjects: 50
Study 22169414 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 25)
Number of subjects: 50
Study 19494028 — intervention group
Group type: EXPERIMENTAL
Intervention: CLA-mix (5.5 g/d of 40/40% of cis9,trans11-CLA and trans10,cis12-CLA)
Number of subjects: 81
Study 19494028 — intervention group
Group type: COMPARATOR
Intervention: Control (olive oil)
Number of subjects: 81
Study 16340945 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity lifestyle intervention
Number of subjects: 915
Study 16340945 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity lifestyle intervention
Number of subjects: 915
Study 16340945 — intervention group
Group type: EXPERIMENTAL
Intervention: MTHFR TT genotype
Number of subjects: 915
Study 16340945 — intervention group
Group type: EXPERIMENTAL
Intervention: MTHFR CC/CT genotype
Number of subjects: 915
Study 16340945 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in biological CVD risk markers
Number of subjects: 915
Study 17986538 — intervention group
Group type: EXPERIMENTAL
Intervention: Mupirocin ointment applied once daily after routine dressing (Group M)
Number of subjects: 154
Study 17986538 — intervention group
Group type: COMPARATOR
Intervention: Usual daily exit-site care without mupirocin (Group C)
Number of subjects: 154
Study 11096195 — intervention group
Group type: EXPERIMENTAL
Intervention: PVP-I liposome hydrogel
Number of subjects: 35
Study 11096195 — intervention group
Group type: COMPARATOR
Intervention: Bactigras
Number of subjects: 35
Study 8813867 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone treatment
Number of subjects: 15
Study 8813867 — intervention group
Group type: COMPARATOR
Intervention: Untreated short controls
Number of subjects: 15
Study 8813867 — intervention group
Group type: COMPARATOR
Intervention: Average controls (10th‐90th centiles)
Number of subjects: 15
Study 8813867 — intervention group
Group type: COMPARATOR
Intervention: Both short groups (treated and untreated)
Number of subjects: 15
Study 8813867 — intervention group
Group type: EXPERIMENTAL
Intervention: Treated children
Number of subjects: 15
Study 1399992 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% lidocaine applied to the oral and nasal mucosa
Number of subjects: 6
Study 1399992 — intervention group
Group type: COMPARATOR
Intervention: Saline (sham anesthesia)
Number of subjects: 6
Study 3895664 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine (CsA)
Number of subjects: 0
Study 3895664 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine and low-dose prednisolone
Number of subjects: 0
Study 3895664 — intervention group
Group type: EXPERIMENTAL
Intervention: Conversion to Azathioprine (AP)
Number of subjects: 0
Study 31592887 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure (PE)
Number of subjects: 104
Study 31592887 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality Exposure (VRE)
Number of subjects: 104
Study 31592887 — intervention group
Group type: COMPARATOR
Intervention: Waitlist Control
Number of subjects: 104
Study 29860967 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular strategy (immediate CT followed by endovascular repair if anatomically suitable)
Number of subjects: 613
Study 29860967 — intervention group
Group type: COMPARATOR
Intervention: Open repair (CT optional)
Number of subjects: 613
Study 29860967 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular strategy
Number of subjects: 613
Study 29860967 — intervention group
Group type: COMPARATOR
Intervention: Open repair
Number of subjects: 613
Study 29860967 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular strategy (for proven rupture)
Number of subjects: 613
Study 28166780 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein diet (1.3 g/kg body weight) with resistance exercise 3 times/week
Number of subjects: 100
Study 28166780 — intervention group
Group type: COMPARATOR
Intervention: High protein diet (1.3 g/kg body weight) without resistance exercise
Number of subjects: 100
Study 28166780 — intervention group
Group type: COMPARATOR
Intervention: Normal protein diet (0.8 g/kg) with resistance exercise 3 times/week
Number of subjects: 100
Study 28166780 — intervention group
Group type: COMPARATOR
Intervention: Normal protein diet (0.8 g/kg) without resistance exercise
Number of subjects: 100
Study 25993609 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 24 U (CFL only)
Number of subjects: 684
Study 25993609 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 44 U (CFL + GL)
Number of subjects: 684
Study 25993609 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 684
Study 23401603 — intervention group
Group type: EXPERIMENTAL
Intervention: Perfusion MRI at rest
Number of subjects: 63
Study 21910743 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic irrigation with 1% sodium hypochlorite for 3 min
Number of subjects: 60
Study 21910743 — intervention group
Group type: COMPARATOR
Intervention: RinsEndo with 1% sodium hypochlorite for 3 min
Number of subjects: 60
Study 18059467 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid levels on day 7 of age during parenteral nutrition phase
Number of subjects: 122
Study 16226864 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast spinal injection (20 seconds) of 10 mg of hyperbaric bupivacaine 0.5% with 25 microg of fentanyl and 100 microg of morphine (group R)
Number of subjects: 60
Study 16226864 — intervention group
Group type: COMPARATOR
Intervention: Slow spinal injection (60 seconds) of 10 mg of hyperbaric bupivacaine 0.5% with 25 microg of fentanyl and 100 microg of morphine (group L)
Number of subjects: 60
Study 14505907 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5mg dose of L2-108/120 peptide
Number of subjects: 13
Study 14505907 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1mg dose of L2-108/120 peptide
Number of subjects: 13
Study 14505907 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 11514043 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptococcus pneumoniae conjugate vaccine
Number of subjects: 9000
Study 11514043 — intervention group
Group type: COMPARATOR
Intervention: Vaccine intervention
Number of subjects: 9000
Study 9032509 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 12
Study 9032509 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 9032509 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole
Number of subjects: 12
Study 9032509 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 12
Study 8286257 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical preparations of highly purified omega-3-PUFA (1% or 10%)
Number of subjects: 52
Study 8286257 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 3492497 — intervention group
Group type: EXPERIMENTAL
Intervention: Urea administered during cardiopulmonary bypass (CPB)
Number of subjects: 75
Study 3492497 — intervention group
Group type: COMPARATOR
Intervention: Control (no urea)
Number of subjects: 75
Study 28944563 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa (10 or 15 mg/kg/day)
Number of subjects: 78
Study 28944563 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 26636922 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-in-oil emulsion
Number of subjects: 0